Date:6/10/2009

, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

'/>"/>

SOURCE Delcath Systems, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
2. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
3. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Delcath Systems Granted Third Orphan Drug Designation
7. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
8. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB